If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
The Swiss biotech company’s priority development drug increases local blood flow in the wound area and addresses impaired blood flow, a central problem in non-healing wounds. The compound under development has a unique mode of action and unprecedented efficacy to enable wound healing. The SME is looking for pharmaceutical corporations for licensing or financial agreements and universities for a research cooperation agreement to bring additional proof of concept and validation in animal studies.
Diabetes mellitus is one of the major health concerns worldwide affecting 425 million people and its prevalence is expected to increase to 629 million by 2045. It is estimated that 12% of the global health expenditure is spent on diabetes (around $727 billion). One serious complication of diabetes mellitus is the diabetic foot ulcer (DFU). Impaired local blood circulation and the resulting low tissue oxygenation, nutrient supply and waste elimination is a major cause for compromised wound healing in diabetic patients and wounds often become chronic and non-healing. Approximately 15% of all diabetic patients will develop an ulcer in their life time. DFU is the most common reasons for hospitalisation and the most frequent cause of lower extremity amputations (LEAs). In fact, every 20 seconds a lower limb is lost due to diabetes somewhere in the world. In spite of significant improvements with current Standard of Care (SoC) there remains a pressing need for innovative treatments.
The Swiss biotech start-up company is developing therapies for the treatment of severe wounds. Based on preclinical studies on vascular smooth muscle cells, isolated organ studies and animal models, the low molecular weight clinical candidate showed increased efficacy and potency on angiogenesis when compared to reference compounds or vehicles. Therapies based on the drug candidate are expected to provide significant benefit on top of existing treatment options for wound healing and prophylaxis of diabetic foot ulcer. Other applications may include erectile dysfunction, pulmonary hypertension and medical cosmetics.
The partner sought could be a large Pharma concern interested in:
- A license agreement to commercialize the technology
- A research cooperation agreement to launch clinical trials
- A financial agreement to move to the next clinical phases
The company is as well evaluating additional academic research cooperation to strengthen the scientific understanding of the unique mode of action.
Drugs improving compromised local endothelial dysfunction, microcirculation and angiogenesis are not approved and commercialised for DFU. The current SoC treatments include:
- Skin substitutes
- Growth factors
- Negative-pressure wound therapy (NPWT)
- Herbal medicine
Despite these achievements, there remains a pressing need for innovative and improved `Medicine that Matters` in DFU targeting key disease mechanisms in this ailment. The elevated number of LEA for DFU underscores the urgency to deliver new drugs with a significant therapeutic advantage when added to SoC.
Therapies based on the new drug are expected to provide significant benefit on top of existing treatment options for wound healing and prophylaxis of diabetic foot ulcers by improving microcirculation and fostering angiogenesis at the wound area.
Tested in vitro (vascular smooth cells) and in wound healing animal models.
The specific area of activity of the partner:
Pharmaceutical companies, universities and R&D organisations with expertise in wound healing:
1. R&D in wound healing
2. Good Manufacturing Practise (GMP) production of microparticles
3. Preparation and execution of Clinical Trials
4. Commercialisation of an innovative drug
The tasks to be performed by the partner sought:
1. Development of a slow-release formulation
2. In-vivo studies in wound healing animal model
3. Development of Clinical Trials Phase I and II